ThromboGenics, Novartis sales and marketing update

ThromboGenics said Novartis' Alcon Inc. unit launched Jetrea ocriplasmin in Germany to treat vitreomacular traction, including when associated with a macular hole of 400 µm or less in diameter. The European Commission approved the product in March (see BioCentury, March 18). ...